Moderna's melanoma vaccine combo cuts recurrence risk about 42% in Phase 3
TradingView reports Moderna's Phase 3 melanoma vaccine with Keytruda cut recurrence or death risk about 42%; analysts split on Citi, Bernstein and TD Cowen views.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the Phase 3 trial of Moderna's combination vaccine with Keytruda cut the risk of melanoma recurrence or death by about 42%, and the risk of distant metastasis by about 38%. The study enrolled more than 1,100 patients. Two-year recurrence-free survival reached 82.2% versus 70%, while overall survival data remain immature.
Analysts are divided. Citi sees a clinically meaningful benefit but keeps a Sell rating and questions whether individualized tumor harvesting and manufacturing are justified. Bernstein calls the results strong validation of the individualized neoantigen platform and keeps a Market Perform rating with a $45 target. TD Cowen keeps a Hold rating and a $90 target. MRNA fell below its 20-day moving average after the leaked data, then rebounded.
why it matters
For investors, the key question is the economics of a personalized vaccine. Manufacturing takes about six weeks, and the stock remains sensitive to valuation and expectations for future cash flows, even though the clinical results were positive.
market impact
Moderna: Phase 3 data shape the company's valuation and expectations for cancer immunotherapy
tags
instruments
sources
- Key facts: MRNA melanoma combo ~42% risk cut; EU, FDA ok; Citi Sell — TradingView, 24 October 2026 at 07:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗